LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

38.87 0.6

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

37.11

Max

38.94

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
EPS	-0.5
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+34.31% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	408M 6B
Iepriekšējā atvēršanas cena	38.27
Iepriekšējā slēgšanas cena	38.87

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2026. g. 2. marts 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2026. g. 2. marts 23:26 UTC

Galvenie ziņu notikumi

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2026. g. 2. marts 22:41 UTC

Tirgus saruna

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2026. g. 2. marts 22:21 UTC

Tirgus saruna

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2026. g. 2. marts 22:10 UTC

Iegādes, apvienošanās, pārņemšana

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2026. g. 2. marts 22:06 UTC

Tirgus saruna

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 2. marts 21:35 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2026. g. 2. marts 21:34 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2026. g. 2. marts 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 21:17 UTC

Galvenie ziņu notikumi

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2026. g. 2. marts 20:44 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2026. g. 2. marts 20:28 UTC

Peļņas

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2026. g. 2. marts 20:25 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2026. g. 2. marts 20:24 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 20:12 UTC

Galvenie ziņu notikumi

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2026. g. 2. marts 20:05 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

34.31% augšup

Prognoze 12 mēnešiem

Vidējais 52.18 USD 34.31%

Augstākais 67 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.